BRAINSTORM CELL THERAPEUTICS (BCLI) Stock Analyst Ratings
USA - NASDAQ:BCLI - US10501E3009 - Common Stock
1.17 USD
-0.03 (-2.5%)
0.67 USD
-0.5 (-42.74%)
ChartMill assigns a Buy % Consensus number of 83% to BCLI. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 15.47. This target is 1222.51% above the current price.
BCLI was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about BCLI.
In the previous month the buy percentage consensus was at a similar level.
BCLI was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-07-23 | Maxim Group | Downgrade | Buy -> Hold |
| 2024-07-11 | Maxim Group | Upgrade | Hold -> Buy |
| 2023-09-28 | Maxim Group | Downgrade | Buy -> Hold |
| 2023-03-31 | Maxim Group | Maintains | Buy |
BRAINSTORM CELL THERAPEUTICS / BCLI FAQ
What is the average price target for BRAINSTORM CELL THERAPEUTICS (BCLI) stock?
7 analysts have analysed BCLI and the average price target is 15.47 USD. This implies a price increase of 1222.51% is expected in the next year compared to the current price of 1.17.
What is the consensus rating for BCLI stock?
The consensus rating for BRAINSTORM CELL THERAPEUTICS (BCLI) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.